This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are Options Traders Betting on a Big Move in HCA Healthcare Stock?
by Zacks Equity Research
Investors need to pay close attention to HCA Healthcare stock based on the movements in the options market lately.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
HUM Misses Q2 Earnings on Higher Benefit Costs, Ups '25 EPS View
by Zacks Equity Research
Humana's Q2 earnings fall year over year on a declining membership base. Notably, 2025 adjusted EPS is currently forecasted at around $17.00, up from the earlier view of around $16.25.
ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%
by Zacks Equity Research
Ensign Group's Q2 earnings improve 20.5% year over year, fueled by stronger occupancy, patient days and rental revenues.
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
by Zacks Equity Research
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
HCA Healthcare (HCA) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of +10.50% and +0.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why HCA Healthcare (HCA) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Ahead of HCA (HCA) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top-and-bottom-line estimates for HCA (HCA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Tenet Healthcare (THC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of +41.55% and +2.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health and Community Health Systems
by Zacks Equity Research
Despite industry pressures, HCA, THC, UHS, and CYH are leveraging M&A, tech, and rising demand to drive resilient growth.
HCA Healthcare to Report Q2 Earnings: Key Estimates to Note
by Zacks Equity Research
The Zacks Consensus Estimate for HCA's Q2 EPS and revenues suggests a year-over-year upside despite higher costs and surgery volume pressure.
Hospital Market May Be Sick, But These 4 Stocks Are Healthy
by Kaibalya Pravo Dey
HCA, THC, UHS, and CYH are showing strength through smart expansions and solid earnings despite hospital industry headwinds.
HCA Healthcare (HCA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
HCA (HCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
June Jobs Data Puts Focus on Healthcare ETFs & Stocks
by Sanghamitra Saha
June's solid jobs report, with 39K new roles in healthcare, may boost the outlook for ETFs like XLV, IHF, VHT and stocks like HCA, WELL, OHI.
Here's Why HCA Healthcare (HCA) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Top Analyst Reports for Johnson & Johnson, Home Depot and Micron
by Mark Vickery
MU gains 42.5% YTD as AI demand fuels DRAM growth, while JNJ and HD navigate pricing, pipeline, and macro headwinds.
Here's Why HCA Healthcare (HCA) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why HCA Healthcare (HCA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Here's How Much a $1000 Investment in HCA Healthcare Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Why HCA Healthcare (HCA) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why HCA Healthcare (HCA) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.